Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Invest New Drugs. 2015 Dec 14;34(2):168–175. doi: 10.1007/s10637-015-0314-7

Table 3.

Drug-related adverse events, worst grade per patient per cycle 1.

Selected Toxicities Dose level 1 (n = 7) Dose level 2 (n = 4) Dose level 3a (n = 22) Total (n = 33), %

G1 G2 G3/4 G1 G2 G3/4 G1 G2 G3/4
Hematologic
 Neutropenia 1 3
 Anemia 3 9
 Thrombocytopenia 1 3
Non-Hematologic
 Nausea 2 10 1 1 42
 Vomiting 1 1 5 5 36
 Diarrhea 3 3 7 5 1 58
 Acneiform Rash 5 2 1 3 12 8 1* 97
 Dry Skin 2 1 1 2 1 21
 Headache 1 1 2 12
 Fever 3 1 1 15
 Fatigue 1 1 2 9 4 1 55
 Mucositis 1 2 9
 Blurry Vision 1 3 12
 Hypokalemia 2 6
 Hypophosphatemia 1 3
 Hyponatremia 1 2 9
 Hypomagnesemia 1* 4 15
 Transaminitis 2 3 3 24

AEs at least possibly related to drug were included.

a

Includes patients at dose level 3 and the dose expansion cohort

*

DLT